Rapt Therapeutics Inc (RAPT) Stock Price, Quote & News

Company Profile

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its l...

Industry: Biotechnology

Sector: Healthcare

Phone: 650-489-9000

Website: www.rapt.com

Address:

561 Eccles Avenue, South San Francisco, United States

bettyandrews92 Oct. 24 at 3:01 PM

$RAPT The read is IR to revenue conversion not just talk. After a two day run of 1x1s you typically see 20 to 30 outbound follow ups and 3 to 5 institutions start real diligence. That maps to EU orders rising from hundreds to low thousands of kits per month within 60 days

0 · Reply

victor32 Oct. 23 at 7:46 PM

$RAPT "Hopefully, following the close of today’s offering, we’ll begin to see some upward movement."

0 · Reply

Izaiah_Sparks_85 Oct. 23 at 4:15 PM

$RAPT

0 · Reply

DonCorleone77 Oct. 22 at 12:50 PM

$RAPT Rapt Therapeutics 8.333M share Spot Secondary priced at $30.00

0 · Reply

TigerOfChicago Oct. 22 at 11:54 AM

$PSTV $AIRE is about to rocket 🚀 $BYND $RAPT $AAPL

0 · Reply

TigerOfChicago Oct. 22 at 11:23 AM

$RAPT I don’t think $BYND will stop it’s going towards 10 plus $PSTV $AIRE

0 · Reply

nUme22 Oct. 21 at 8:42 PM

$RAPT public offering.. not good. will be back to 20 now.

1 · Reply

AStrokeOfLuck Oct. 21 at 8:27 PM

$RAPT https://www.sec.gov/Archives/edgar/data/1673772/000119312525245097/d44203d424b5.htm

0 · Reply

FilingTracker Oct. 21 at 8:03 PM

$RAPT RAPT Therapeutics Announces Proposed Public Offering of Common Stock: https://www.globenewswire.com/news-release/2025/10/21/3170617/0/en/RAPT-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html

0 · Reply

anachartanalyst Oct. 21 at 2:02 PM

$RAPT https://anachart.com/wp-content/uploads/ana_temp/1761055319_soc-img.jpg

0 · Reply

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

Oct 21, 2025, 4:01 PM EDT - 4 days ago

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

Oct 20, 2025, 5:05 PM EDT - 4 days ago

RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript

Oct 20, 2025, 9:42 AM EDT - 5 days ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC CRMD RANI

Oct 20, 2025, 8:00 AM EDT - 5 days ago

RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

Oct 19, 2025, 8:00 AM EDT - 6 days ago

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

Sep 29, 2025, 5:00 AM EDT - 26 days ago

RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

Aug 27, 2025, 8:00 AM EDT - 2 months ago

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

Aug 7, 2025, 8:00 AM EDT - 2 months ago

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

Jun 23, 2025, 8:00 AM EDT - 4 months ago

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

Jun 13, 2025, 9:00 AM EDT - 4 months ago

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

Jun 4, 2025, 4:05 PM EDT - 5 months ago

RAPT Therapeutics to Participate in Upcoming Investor Conferences

May 8, 2025, 8:00 AM EDT - 6 months ago

RAPT Therapeutics Reports First Quarter 2025 Financial Results

Apr 15, 2025, 8:00 AM EDT - 6 months ago

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

Mar 6, 2025, 8:00 AM EST - 8 months ago

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 9, 2025, 8:00 AM EST - 10 months ago

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:00 AM EST - 10 months ago

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

Dec 23, 2024, 7:10 AM EST - 10 months ago

RAPT Therapeutics Announces $150 Million Private Placement

Nov 11, 2024, 10:34 AM EST - 1 year ago

Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury

Jul 24, 2024, 6:32 PM EDT - 1 year ago

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

May 21, 2024, 8:39 AM EDT - 1 year ago

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)

BAX SAGE TMCI LNAI

May 20, 2024, 4:35 AM EDT - 1 year ago

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

May 9, 2024, 8:00 AM EDT - 1 year ago

RAPT Therapeutics Reports First Quarter 2024 Financial Results

Apr 9, 2024, 12:00 PM EDT - 1 year ago

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Apr 2, 2024, 2:10 AM EDT - 1 year ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT JANX VKTX AMLX MCRB RVNC

Mar 7, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 5, 2024, 4:30 PM EST - 1 year ago

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

Feb 26, 2024, 4:00 AM EST - 1 year ago

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Feb 20, 2024, 8:36 AM EST - 1 year ago

RAPT Therapeutics' stock plunges as FDA halts two clinical trials

Feb 20, 2024, 7:41 AM EST - 1 year ago

FDA puts on hold two Rapt Therapeutics mid-stage drug trials

Feb 20, 2024, 7:30 AM EST - 1 year ago

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

Feb 13, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

Jan 31, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 2, 2024, 8:00 AM EST - 1 year ago

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 27, 2023, 8:00 AM EST - 2 years ago

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

Nov 13, 2023, 8:00 AM EST - 2 years ago

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

Nov 3, 2023, 12:00 PM EDT - 2 years ago

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

Nov 1, 2023, 4:05 PM EDT - 2 years ago

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November

Oct 18, 2023, 9:00 AM EDT - 2 years ago

RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Aug 30, 2023, 4:05 PM EDT - 2 years ago

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

Aug 11, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports Second Quarter 2023 Financial Results

Jun 13, 2023, 3:59 PM EDT - 2 years ago

RAPT Therapeutics: Major Catalysts Are A Long Way Off

Jun 7, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 2 years ago

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

May 11, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Reports First Quarter 2023 Financial Results

May 3, 2023, 8:00 AM EDT - 2 years ago

RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

Apr 26, 2023, 4:19 PM EDT - 2 years ago

RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 30, 2023, 12:12 AM EDT - 2 years ago

RAPT Therapeutics: Potential Strong Upside Ahead

bettyandrews92 Oct. 24 at 3:01 PM

0 · Reply

victor32 Oct. 23 at 7:46 PM

$RAPT "Hopefully, following the close of today’s offering, we’ll begin to see some upward movement."

0 · Reply

Izaiah_Sparks_85 Oct. 23 at 4:15 PM

$RAPT

0 · Reply

DonCorleone77 Oct. 22 at 12:50 PM

$RAPT Rapt Therapeutics 8.333M share Spot Secondary priced at $30.00

0 · Reply

TigerOfChicago Oct. 22 at 11:54 AM

$PSTV $AIRE is about to rocket 🚀 $BYND $RAPT $AAPL

0 · Reply

TigerOfChicago Oct. 22 at 11:23 AM

$RAPT I don’t think $BYND will stop it’s going towards 10 plus $PSTV $AIRE

0 · Reply

nUme22 Oct. 21 at 8:42 PM

$RAPT public offering.. not good. will be back to 20 now.

1 · Reply

AStrokeOfLuck Oct. 21 at 8:27 PM

$RAPT https://www.sec.gov/Archives/edgar/data/1673772/000119312525245097/d44203d424b5.htm

0 · Reply

FilingTracker Oct. 21 at 8:03 PM

0 · Reply

anachartanalyst Oct. 21 at 2:02 PM

$RAPT https://anachart.com/wp-content/uploads/ana_temp/1761055319_soc-img.jpg

0 · Reply

TigerOfChicago Oct. 21 at 1:39 PM

$RAPT I like $BYND as well

0 · Reply

JarvisFlow Oct. 21 at 1:08 PM

Wells Fargo has updated their rating for RAPT Therapeutics ( $RAPT ) to Overweight with a price target of 48.

0 · Reply

JarvisFlow Oct. 21 at 12:47 PM

Barclays updates rating for RAPT Therapeutics ( $RAPT ) to Overweight, target set at 35 → 58.

0 · Reply

JarvisFlow Oct. 21 at 11:35 AM

Clear Street has adjusted their stance on RAPT Therapeutics ( $RAPT ), setting the rating to Buy with a target price of 41 → 60.

0 · Reply

Quantumup Oct. 21 at 10:13 AM

JPMorgan y'day⬆️ $RAPT OW-$55 from N-$13/said Ph2 data for RPT904 in CSU is very compelling—believes data de-risks RAPT's broader pipeline—finds shrs attractive at current levels—ests peak sales of $2.X.5B & $400M in food allergy/CSU. $NVS Wells Fargo⬆️to $48/reit'd OW Barclays y'day⬆️to $58 from $35/reit'd OW Wells Fargo and Barclays said:

0 · Reply

KingsOnly Oct. 21 at 10:02 AM

$RAPT RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

0 · Reply

BayAreaBiotech Oct. 21 at 3:15 AM

$RAPT we have come a long way in the last three weeks. After holding this for almost 18 months, it has started to pay off. Those who have held during the down time and have been patient are seeing the rewards. I regret selling half of my shares in late September but it’s impossible to predict the stock price.

0 · Reply

arthurkorff Oct. 20 at 10:20 PM

$RAPT was there an offering?

0 · Reply

victor32 Oct. 20 at 10:08 PM

$RAPT over $40 tomorrow

0 · Reply

JarvisFlow Oct. 20 at 9:59 PM

JP Morgan has adjusted their stance on RAPT Therapeutics ( $RAPT ), setting the rating to Overweight with a target price of 13 → 55.

0 · Reply

UgoGreg Oct. 20 at 8:07 PM

$RAPT https://youtu.be/NjikYUHy2Zc

0 · Reply

Gbang77 Oct. 20 at 7:17 PM

$RAPT Rode this $32 to $37 this morning. Got out as soon as I could after being down 17%, with Webull glitching.

0 · Reply

Market Cap	496.14M
Revenue (ttm)	0.00
Net Income (ttm)	-129.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	555,100
Avg Vol	364,472
Day's Range	N/A - N/A
Shares Out	16.54M
Stochastic %K	27%
Beta	0.23
Analysts	Strong Sell
Price Target	$53.33